BTK Mutation Detection for Ibrutinib Resistance and Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments with BTK inhibitors like Ibrutinib face resistance due to mutations in the kinase domain of Bruton's Tyrosine Kinase (BTK), particularly at position C481, leading to leukemia progression and Richter transformation, with unclear mechanisms of cancer relapse and resistance.
Innovation Solution
Identification and characterization of mutations, such as BTKT316A in the SH2 domain, which confer resistance to BTK inhibitors, allowing for methods to determine resistance, optimize therapy, and select appropriate inhibitors, including second-generation BTK inhibitors for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BTK inhibitors like Ibrutinib are used to treat B-cell malignancies, then response rates are improved, but resistance develops due to BTK mutations
Solution Approach 1:
The patent applies parameter changes by developing second-generation BTK inhibitors with modified chemical structures and binding characteristics that can effectively inhibit mutant BTK forms (such as C481S, C481Y, C481A mutations) that resist first-generation inhibitors like ibrutinib. This involves altering the inhibitor's molecular parameters to maintain binding affinity while overcoming mutation-induced resistance.
Solution Approach 2:
The patent employs dynamics by creating a sequential treatment strategy where patients can transition from first-generation to second-generation BTK inhibitors based on resistance development. This dynamic approach allows the treatment regimen to adapt over time, switching therapeutic agents in response to observed resistance patterns while maintaining continuous targeted inhibition of BTK signaling.
2Stability of the object's composition
If BTK inhibitors are administered, then cancer progression is initially controlled, but leukemia progression and Richter transformation occur due to resistance
Solution Approach 1:
The patent applies preliminary action by implementing resistance monitoring programs that detect BTK mutation development before clinical progression occurs. Through regular genetic testing of patient samples, the system can identify emerging resistance mutations (such as in the kinase domain) and pre-emptively switch to appropriate second-generation inhibitors, preventing disease progression and Richter transformation before they manifest clinically.
Solution Approach 2:
The patent employs feedback mechanisms by using patient response data and genetic profiling to continuously adjust treatment strategies. When resistance is detected through monitoring of BTK mutation status or disease progression markers, the system provides feedback to switch from first-generation to second-generation inhibitors, creating a closed-loop treatment approach that adapts to individual patient needs and maintains long-term disease control.
3Object-affected harmful factors
If treatment is discontinued due to resistance, then further progression is prevented, but patient outcomes deteriorate without effective therapy
Solution Approach 1:
The patent applies the intermediary principle by introducing second-generation BTK inhibitors as mediator agents that can effectively target mutant BTK forms resistant to first-generation inhibitors. These second-generation inhibitors serve as intermediate therapeutic solutions that bridge the gap when resistance develops, allowing continued effective treatment rather than complete therapy discontinuation, thereby maintaining patient outcomes while preventing disease progression.
Data Source
AI summary
Provided herein are mutations in Bruton's Tyrosine Kinase (BTK) that confer resistance to treatment with a BTK inhibitors, such as Ibrutinib, and compositions and methods for the treatment, diagnosis, and characterization of BTK-inhibitor-resistant cancers.